• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镭-223可诱导几种前列腺癌细胞系发生聚集性DNA损伤并抑制细胞存活。

Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines.

作者信息

Abramenkovs Andris, Hariri Mehran, Spiegelberg Diana, Nilsson Sten, Stenerlöw Bo

机构信息

Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala SE-75185, Sweden.

Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala SE-75185, Sweden.

出版信息

Transl Oncol. 2022 Dec;26:101543. doi: 10.1016/j.tranon.2022.101543. Epub 2022 Sep 18.

DOI:10.1016/j.tranon.2022.101543
PMID:36126563
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9489499/
Abstract

The bone-seeking radiopharmaceutical Xofigo (Radium-223 dichloride) has demonstrated both extended survival and palliative effects in treatment of bone metastases in prostate cancer. The alpha-particle emitter Ra-223, targets regions undergoing active bone remodeling and strongly binds to bone hydroxyapatite (HAp). However, the toxicity mechanism and properties of Ra-223 binding to hydroxyapatite are not fully understood. By exposing 2D and 3D (spheroid) prostate cancer cell models to free and HAp-bound Ra-223 we here studied cell toxicity, apoptosis and formation and repair of DNA double-strand breaks (DSBs). The rapid binding with a high affinity of Ra-223 to bone-like HAp structures was evident (KD= 19.2 × 10 M) and almost no dissociation was detected within 24 h. Importantly, there was no significant uptake of Ra-223 in cells. The Ra-223 alpha-particle decay produced track-like distributions of the DNA damage response proteins 53BP1 and ɣH2AX induced high amounts of clustered DSBs in prostate cancer cells and activated DSB repair through non-homologous end-joining (NHEJ). Ra-223 inhibited growth of prostate cancer cells, independent of cell type, and induced high levels of apoptosis. In summary, we suggest the high cell killing efficacy of the Ra-223 was attributed to the clustered DNA damaged sites induced by α-particles.

摘要

亲骨性放射性药物Xofigo(二氯化镭-223)已在前列腺癌骨转移的治疗中显示出延长生存期和姑息治疗效果。α粒子发射体镭-223靶向进行活跃骨重塑的区域,并与骨羟基磷灰石(HAp)紧密结合。然而,镭-223与羟基磷灰石结合的毒性机制和特性尚未完全明确。通过将二维和三维(球体)前列腺癌细胞模型暴露于游离的和与HAp结合的镭-223中,我们在此研究了细胞毒性、细胞凋亡以及DNA双链断裂(DSB)的形成与修复。镭-223与类骨HAp结构的快速高亲和力结合很明显(KD = 19.2×10 M),并且在24小时内几乎未检测到解离。重要的是,细胞对镭-223没有明显摄取。镭-223的α粒子衰变产生了DNA损伤反应蛋白53BP1和ɣH2AX的轨迹样分布,在前列腺癌细胞中诱导了大量成簇的DSB,并通过非同源末端连接(NHEJ)激活了DSB修复。镭-223抑制前列腺癌细胞生长,与细胞类型无关,并诱导高水平的细胞凋亡。总之,我们认为镭-223的高细胞杀伤效力归因于α粒子诱导的成簇DNA损伤位点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/ad249aacf224/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/db4df5b28c27/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/57d301a1c5cb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/909c9187b526/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/663d2c5595df/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/ad249aacf224/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/db4df5b28c27/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/57d301a1c5cb/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/909c9187b526/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/663d2c5595df/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7eb8/9489499/ad249aacf224/gr5.jpg

相似文献

1
Ra-223 induces clustered DNA damage and inhibits cell survival in several prostate cancer cell lines.镭-223可诱导几种前列腺癌细胞系发生聚集性DNA损伤并抑制细胞存活。
Transl Oncol. 2022 Dec;26:101543. doi: 10.1016/j.tranon.2022.101543. Epub 2022 Sep 18.
2
Repair of HZE-particle-induced DNA double-strand breaks in normal human fibroblasts.重离子束(HZE)粒子诱导的正常人成纤维细胞DNA双链断裂的修复
Radiat Res. 2008 Apr;169(4):437-46. doi: 10.1667/RR1165.1.
3
Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone.镭-223 二氯化物骨靶向 α 粒子治疗激素难治性乳腺癌骨转移。
Exp Hematol Oncol. 2014 Sep 8;3:23. doi: 10.1186/2162-3619-3-23. eCollection 2014.
4
Correlation of the absorbed dose to the blood and DNA damage in leukocytes after internal ex-vivo irradiation of blood samples with Ra-224.用Ra-224对血液样本进行体外照射后,白细胞中血液吸收剂量与DNA损伤的相关性。
EJNMMI Res. 2018 Aug 6;8(1):77. doi: 10.1186/s13550-018-0422-4.
5
Clustered DNA damage concentrated in particle trajectories causes persistent large-scale rearrangements in chromatin architecture.聚集的 DNA 损伤集中在粒子轨迹中,导致染色质结构中持续的大规模重排。
Radiother Oncol. 2018 Dec;129(3):600-610. doi: 10.1016/j.radonc.2018.07.003. Epub 2018 Jul 23.
6
Radiobiological effects of the alpha emitter Ra-223 on tumor cells.镭-223α 发射器对肿瘤细胞的放射生物学效应。
Sci Rep. 2019 Dec 6;9(1):18489. doi: 10.1038/s41598-019-54884-7.
7
α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [Ra]RaCl-treated prostate cancer patients.α-粒子诱导的 DNA 损伤在[Ra]RaCl 治疗的前列腺癌患者外周血单个核细胞中的轨迹。
Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2761-2770. doi: 10.1007/s00259-020-05170-6. Epub 2021 Feb 4.
8
DNA damage in leukocytes after internal ex-vivo irradiation of blood with the α-emitter Ra-223.α 发射体镭-223 对离体血液内照射后白细胞中的 DNA 损伤。
Sci Rep. 2018 Feb 2;8(1):2286. doi: 10.1038/s41598-018-20364-7.
9
Nanostructure of Clustered DNA Damage in Leukocytes after In-Solution Irradiation with the Alpha Emitter Ra-223.用α发射体Ra-223进行溶液内照射后白细胞中聚集性DNA损伤的纳米结构
Cancers (Basel). 2019 Nov 26;11(12):1877. doi: 10.3390/cancers11121877.
10
The role of nonhomologous DNA end joining, conservative homologous recombination, and single-strand annealing in the cell cycle-dependent repair of DNA double-strand breaks induced by H(2)O(2) in mammalian cells.非同源DNA末端连接、保守同源重组和单链退火在哺乳动物细胞中由H₂O₂诱导的DNA双链断裂的细胞周期依赖性修复中的作用。
Radiat Res. 2008 Dec;170(6):784-93. doi: 10.1667/RR1375.1.

引用本文的文献

1
Targeted alpha therapy: a comprehensive analysis of the biological effects from "local-regional-systemic" dimensions.靶向α治疗:从“局部-区域-全身”维度对生物学效应的综合分析
Eur J Nucl Med Mol Imaging. 2025 Jun 11. doi: 10.1007/s00259-025-07390-0.
2
Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy.增强胶质母细胞瘤治疗效果:揭示奥纳莱斯匹布与放射治疗联合疗法的协同抗癌作用。
Front Oncol. 2025 Jan 30;15:1451156. doi: 10.3389/fonc.2025.1451156. eCollection 2025.
3
Radiopharmaceuticals and their applications in medicine.
放射性药物及其在医学中的应用。
Signal Transduct Target Ther. 2025 Jan 3;10(1):1. doi: 10.1038/s41392-024-02041-6.
4
APR-246 as a radiosensitization strategy for mutant p53 cancers treated with alpha-particles-based radiotherapy.APR-246 作为一种放射增敏策略,用于治疗携带突变型 p53 基因的癌症的基于 α 粒子的放射治疗。
Cell Death Dis. 2024 Jun 18;15(6):426. doi: 10.1038/s41419-024-06830-3.
5
Synergistic Activity of DNA Damage Response Inhibitors in Combination with Radium-223 in Prostate Cancer.DNA损伤反应抑制剂与镭-223联合用于前列腺癌的协同活性
Cancers (Basel). 2024 Apr 15;16(8):1510. doi: 10.3390/cancers16081510.
6
Mitofusin 1 silencing decreases the senescent associated secretory phenotype, promotes immune cell recruitment and delays melanoma tumor growth after chemotherapy.沉默线粒体融合蛋白 1 可减少衰老相关分泌表型,促进免疫细胞募集,并在化疗后延缓黑色素瘤肿瘤生长。
Sci Rep. 2024 Jan 9;14(1):909. doi: 10.1038/s41598-024-51427-7.
7
DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair.放射性药物所致DNA损伤及细胞修复机制
Pharmaceutics. 2023 Dec 12;15(12):2761. doi: 10.3390/pharmaceutics15122761.
8
Radiobiological Assessment of Targeted Radionuclide Therapy with [Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models.二维与三维细胞培养模型中[Lu]Lu-PSMA-I&T 靶向放射性核素治疗的放射生物学评估。
Int J Mol Sci. 2023 Nov 30;24(23):17015. doi: 10.3390/ijms242317015.
9
Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates.用于评估抗癌治疗的三维体外肿瘤球体模型:最新进展
Cancers (Basel). 2023 Oct 4;15(19):4846. doi: 10.3390/cancers15194846.
10
Let's Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer.让我们进入 3D 时代!新一代模型用于评估前列腺癌中的药物反应和耐药性。
Int J Mol Sci. 2023 Mar 10;24(6):5293. doi: 10.3390/ijms24065293.